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a b s t r a c t
Increasing numbers of biosimilar medicines are becoming available. The objective of this survey was to
assess awareness of and attitudes to biosimilars amongst physicians (medical specialists and General
Practitioners (GPs)) and community pharmacists in Ireland. Physicians were invited to complete an
online questionnaire during April and May 2016. Community pharmacists received a postal question-
naire in August 2015. Responses from 102 medical specialists, 253 GPs and 125 community pharmacists
were analysed. The majority of medical specialists (85%) and pharmacists (77%) claimed to be either very
familiar or familiar with the term biosimilar, whereas many GPs (60%) were unable to deﬁne or had never
heard of the term. One in ﬁve (21%) healthcare professionals responded that biosimilars were the same as
generic medicines. The majority of medical specialists opposed pharmacist-led substitution of biological
medicines but some thought it could be appropriate if agreed with the clinician in advance. Medical
specialists who prescribe biosimilars (n ¼ 43) were more likely to do so on treatment initiation (67%),
than switch a patient from an originator medicine to a biosimilar (28%). The ﬁndings will aid the design
of educational initiatives for healthcare professionals and highlight attitudes of healthcare professionals
to biosimilars, so informing regulators, policy makers and industry.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In 2006 the ﬁrst biosimilar medicine Omnitrope® (containing
somatropin) was approved for use in Europe. At the time of writing
(June 2017), there were 28 biosimilars, containing 11 active sub-
stances (adalimumab, enoxaparin sodium, epoetin, etanercept, ﬁl-
grastim, follitropin alfa, inﬂiximab, insulin glargine, rituximab,
somatropin and teriparatide), approved in Europe (EMA, 2017c).
This number is expected to grow rapidly in the next few years. As of
June 2017, there are 22 applications for biosimilars under evalua-
tion at the European Medicines Agency (EMA) or awaiting ﬁnal
approval from the European Commission. Many of these products
contain active substances not previously authorised as biosimilars
(bevacizumab, insulin lispro, pegﬁlgrastim, and trastuzumab)
(EMA, 2017a, b). In addition, it is estimated that 50 distinct bio-
similars are in development (IMS Institute, 2016).
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A biosimilar is a biological medicine that contains a version of
the active substance of an already approved original biological
medicine (known as the originator or reference medicine) (EMA,
2014). The heterogeneous nature, high molecular weight, batch-
to-batch variability and complexity of many biological substances
means that it is not possible for a differentmanufacturer tomake an
exact copy of the medicine, therefore, generics of biological medi-
cines are not feasible. In the case of chemically synthesised medi-
cines, approval as a generic is possible once an identical chemical
structure for the active substance has been conﬁrmed and bio-
equivalence to the reference product has been demonstrated
(Schellekens et al., 2016). Owing to the inherent differences be-
tween biological and chemical substances, the abbreviated regu-
latory pathway used for generics is not suitable for copies of
biological substances produced by different manufacturers.
Therefore, biosimilar manufacturers are required to demonstrate,
by way of a comprehensive comparability exercise, that the bio-
similar is similar in quality, safety and efﬁcacy to the reference
medicine. Extensive characterisation and comparison of the phys-
iochemical, structural and functional characteristics (e.g., molecular
structure, receptor binding and biological activity) of the biosimilar
and reference medicine is required. Comparative clinical trials are
conducted in key indications where clinically relevant differences
are most likely to be revealed. Therefore, a biosimilar may be
licensed in therapeutic indications for which no speciﬁc clinical
trials have been conducted. This is known as indication extrapo-
lation and is only approved by regulators after comprehensive
scientiﬁc justiﬁcation, which includes consideration of the mech-
anism of action in each indication (Weise et al., 2014).
A tailored non-clinical and clinical testing programme means
that biosimilars are likely to have reduced development costs in
comparison to their reference medicines. A number of budget
impact analyses have predicted signiﬁcant cost savings from the
introduction of biosimilar medicines into different healthcare sys-
tems (McCarthy et al., 2013; Brodszky et al., 2014; Jha et al., 2015).
Subsequent reports, commissioned by the European Commission,
have found that the introduction of biosimilar competition can
result in lower market prices (IMS Health, 2016; IMS Health, 2017).
Such savings, if re-directed appropriately, could be used to increase
patient access to expensive biological treatments (Haustein et al.,
2012; Gulacsi et al., 2015).
As biosimilars differ from generic medicines it is imperative that
healthcare professionals involved in their use are informed of
considerations relating to their prescribing practices, traceability
and interchangeability (HPRA, 2015). Ongoing pharmacovigilance
activities ensures that the safety of all biological medicines,
including biosimilars, is monitored on an ongoing basis after
approval. Spontaneous reporting of adverse reactions is an impor-
tant component of pharmacovigilance, despite the fact that
underreporting of adverse reactions is a major limitation of such
systems (Gonzalez-Gonzalez et al., 2013). Biological medicines have
speciﬁc pharmacovigilance considerations including immunoge-
nicity, manufacturing variability and stability (EMA, 2016). In order
to evaluate the potential impact of any suspected adverse reactions,
EU pharmacovigilance legislation requires that brand name and
batch number are provided in suspected adverse reaction reports
related to biological medicines. As such, robust traceability systems
are required to ensure these reports are attributed to the correct
medicine. For this reason, physicians are encouraged to prescribe
biological medicines by brand name (HPRA, 2015); and batch
traceability of biological medicines in clinical use needs to be
ensured (EMA, 2016).
In Europe the term ‘interchangeability’ is generally understood
to mean a medical practice of changing one medicine for another
that is expected to achieve the same clinical effect in a given clinical
setting and in any patient on the initiative, or with the agreement of
the prescriber (EC, 2013). Whilst EMA evaluations do not include
recommendations on whether biosimilars can be used inter-
changeably with their reference medicines, several National
Competent Authorities in Europe, including the Irish Health Prod-
ucts Regulatory Authority (HPRA), agree that physicians have the
discretion to change their patient's medicine from the reference
medicine to a biosimilar once their patient is informed (Fimea,
2015; HPRA, 2015; MEB, 2016). Indeed, there is increasing regula-
tory opinion that biosimilars in the EU are interchangeable with
their reference medicines under prescriber supervision with the
caveat that there is appropriate clinical monitoring, and patients
have the necessary information about the medicine, including, if
necessary, training on its administration (Kurki et al., 2017).
In September 2013, inﬂiximab (marketed as Remsima®/Inﬂec-
tra®) was approved as the ﬁrst biosimilar monoclonal antibody
(EMA, 2017c). Medical specialists in disciplines who had previously
no experience with biosimilar medicines, such as gastroenterology,
rheumatology and dermatology, now had a choice over which
brand of inﬂiximab they could prescribe to their patients. Surveys
conducted around this time indicated that somemedical specialists
had misconceptions about biosimilars, or were not conﬁdent in
their use (Danese et al., 2014; Dolinar and Reilly, 2014). A survey of
pharmacists, conducted in France in 2015, found that many phar-
macists claimed to be not familiar with biosimilars. Notable dif-
ferences were observed in responses from community and hospital
pharmacists, as community pharmacists were more likely to state
that they were not at all informed about biosimilars (Beck et al.,
2017). Now that biosimilars are becoming more widely available,
there is a renewed need to assess the awareness of not only medical
specialists but other allied healthcare professionals in relation to
their prescribing, dispensing and traceability. Patients often look to
healthcare professionals as sources of medicines information
(O'Leary et al., 2015). Consequently, medical specialists, GPs and
community pharmacists may need to advise their patients about
biosimilars. The aforementioned issues are especially pertinent in
light of increasing drive to encourage the use of biosimilars in
clinical practice (BSG, 2016; MMP, 2016). Therefore we conducted a
survey of medical specialists, GPs and community pharmacists in
order to assess and compare their awareness of and attitudes to
biosimilars.
2. Methods
Questionnaires were developed after reviewing previous sur-
veys on stakeholder views relating to both biosimilar (Zelenetz
et al., 2011; Dolinar and Reilly, 2014; Fernandez-Lopez et al.,
2015; Grabowski et al., 2015; Hallersten et al., 2016) and generic
medicines (O'Leary et al., 2015). Some questions were modiﬁed to
suit the Irish context and all questions were worded in a neutral
manner.
In August 2015, the market research group, Ipsos MRBI, sent a
questionnaire to a nationwide community pharmacy sample.
Pharmacists who did not respond to the questionnaire received one
telephone reminder. A honorariumwas provided to the pharmacist
respondents.
Questionnaires for physicians (medical specialists and GPs)
were designed after distribution of the pharmacist survey. Relevant
items on the pharmacist questionnaire were included on the
physician questionnaire and in certain cases the questions were
developed further so not all questions were identical. Tailored
questionnaires for medical specialists and GPs were reviewed and
agreed by a panel of 12 experts with clinical, pharmacy, regulatory
and academic backgrounds. Medical specialists who practice in
areas where biological medicines are prescribed were targeted. The
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following groups were invited to participate; dermatologists, en-
docrinologists, gastroenterologists, haematologists, nephrologists,
neurologists, oncologists and rheumatologists. The links to the
online questionnaires for medical specialists and GPs (hosted at
www.surveymonkey.com) were distributed via email by their na-
tional professional societies during April and May 2016. Up to two
reminder emails were sent in this time period. No honorariumwas
provided to the participating physicians.
The pharmacist questionnaire wording was reviewed by the
expert panel and it was agreed results from common questions
could be compared. The three questionnaires are available in the
supplementary material provided. Comparisons between categor-
ical variables were performed using Chi squared test. The research
study was approved by the Social Research Ethics Committee
(SREC) in University College Cork, Ireland.
3. Results
3.1. Sample characteristics
3.1.1. Pharmacists
A total of 143 responses were received from a panel of 200
community pharmacists (72% response rate). The market research
company obtained consent from 125 respondents for their anony-
mised data to be published. Of this number, 90% practised in in-
dependent pharmacies, whereas 10% practised in pharmacy chains.
The majority of pharmacists (96%) conﬁrmed that they currently
dispense biological medicines to patients in their pharmacy.
3.1.2. Physicians
Responses were received from 268 GPs and 109 medical spe-
cialists. The questionnaire for GPs was distributed by the Irish
College of General Practitioners. A total of 2917 GP members were
sent the email invite, corresponding to a response rate of 9%. The
rate of non-participation was not recorded for the medical spe-
cialists as some of the societies were unable to provide exact details
of physician numbers. Physicians who failed to provide full de-
mographic details and complete the question indicating familiarity
with the term biosimilar were eliminated from the analysis.
Consequently, responses from 102 medical specialists and 253 GPs
were analysed. Not all questions required responses and some re-
spondents chose not to answer every question. The medical
specialist respondents were more experienced than GP re-
spondents with 93% having 10 years or more professional experi-
ence compared to 66% of GPs having similar experience. The
majority of GPs (96%) conﬁrmed that they treated patients who
received biological medicines prescribed by a medical specialist.
The demographics of the physician respondents are summarised in
Table 1.
3.2. Familiarity with the term biosimilar
Survey respondents were asked how familiar theywerewith the
term ‘biosimilar’ (Fig. 1). The responses differed across the three
professions. In comparison to GPs, medical specialists and phar-
macists claimed to be more familiar with the term.
Those respondents who answered very familiar or familiar to
the questionwere grouped as ‘familiar’. Thosewho could not deﬁne
or had never heard of the term biosimilar were grouped as ‘unfa-
miliar’. There was no difference between the rate of pharmacists
and medical specialist in terms of reporting that they were
‘familiar’ with the term (75.2% vs. 85.3%, p ¼ ns). However, there
was a signiﬁcant difference between pharmacists and GPs (75.2%
vs. 40.3%, p < 0.001) and between medical specialists and GPs
(85.3% vs. 40.3%, p < 0.001) in terms of the ‘familiar response’.
3.3. Are biosimilars the same as generics?
To gauge actual awareness regarding their understanding of
biosimilars, healthcare professionals were asked if they considered
biosimilars to be the same as generic medicines. Of the healthcare
professionals who responded (n ¼ 410), one in ﬁve (21%) thought a
biosimilar was the same as a generic medicine. There was no sig-
niﬁcant difference in the proportion of pharmacists, general prac-
titioners and medical specialists who responded that biosimilars
are the same as generic medicines (Fig. 2).
3.4. What's in a name?
Survey respondents were asked how they perceived two bio-
logical medicines (e.g. originator and biosimilar) with the same
international nonproprietary name (INN) in relation to structure,
approved indications and clinical efﬁcacy (Fig. 3). Almost half (47%)
of the total respondents incorrectly agreed that biological medi-
cines sharing the same INN were ‘structurally identical’. Analysis of
the responses by profession revealed that pharmacists (50%) were
most likely to agree with this statement whereas medical special-
ists (31%) were least likely. The majority of healthcare professionals
(61%) agreed that two biological medicines with the same INN
would be approved for the same therapeutic indications. GPs (75%)
weremost likely to agree and pharmacists (50%) were least likely to
agree with this statement. In relation to clinical outcome, 43% of
physicians agreed that two biological medicines with the same INN
could be safely received by patients with the same clinical outcome,
whilst 34% chose to neither agree nor disagree with this statement
and 22% disagreed. In relation to switching between two biological
medicines with the same INN, a signiﬁcant proportion of physicians
(42%) were neutral over whether patients could be safely switched
and still achieve the same clinical outcome.
3.5. Pharmacovigilance
In order to evaluate pharmacovigilance recording practices, all
healthcare professionals were asked how they prescribed, recorded
or dispensed biological medicines. It was noted that 7% of medical
specialists, 6% of GPs and 1% of pharmacists failed to provide a
response to this question. Of those healthcare professionals
(n¼ 457) that did respond, most used brand name and INN (36%) or
brand name only (43%) to identify biological medicines. The
remaining respondents indicated that they used INN only (7%) or
responded that their practice in this regard varied by medicine
(14%). Many who chose this option explained theywould use either
brand name or INN depending on their overall familiarity with the
medicine. When asked about adverse reaction reporting, 45% of
medical specialists (n ¼ 46) and 12% of GPs (n ¼ 29) indicated that
they had previously reported a suspected adverse reaction for a
biological medicine. This group of respondents were asked to
clarify what type of information they had previously included in
such reports. Most (82%) stated that they had included the brand
name almost every time or every time. In contrast 57% indicated
that they never or almost never included the batch number. In
Ireland batch numbers for vaccines administered to patients are
routinely recorded in GP surgeries (HSE, 2016). Therefore, in order
to minimise bias, the response in relation to batch numbers
excluded GPs who had only previously reported suspected adverse
reactions for vaccines.
3.6. Prescriber behaviours
Medical specialists, who responded that they were aware of
biosimilars in their speciﬁc therapeutic area (n ¼ 73), were asked
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questions in relation to their prescribing behaviours. Amongst this
group, 59% indicated that they prescribed biosimilars to patients in
their practice, 40% did not and 1% did not know. Those medical
specialists who prescribed biosimilars (n ¼ 43) were asked about
their prescribing patterns (Fig. 4). The majority (67%) responded
that they would be most likely to prescribe a biosimilar on treat-
ment initiationwhereas, in the case of clinically stable patients, 28%
would be likely to switch from an originator to a biosimilar medi-
cine. Some medical specialists (19%) indicated that they would be
likely to switch to a biosimilar if the patient had a poor clinical
response to the originator medicine.
3.7. Attitudes to pharmacist led substitution
The questionnaire for medical specialists explored attitudes
towards pharmacist-led substitution (Fig. 5). Substitution was
deﬁned for respondents as ‘a pharmacist dispensing a biosimilar in
place of an originator medicine (or vice versa) without consulting the
prescriber’. Very fewmedical specialists (<5%) believed substitution
of a biological medicine by a pharmacist could be appropriate. The
majority believed that decisions of this nature should be taken by
the prescriber both on treatment initiation (49%) and during a
patient's treatment course (61%). However, a signiﬁcant proportion
responded that substitution could be appropriate if agreed with the
clinician in advance.
If substitution by a pharmacist did take place, notiﬁcation of this
substitution was considered to be very important or critical by
medical specialists both on treatment initiation (84%) and during a
patient's treatment course (90%). Pharmacists (n¼ 125) were asked
if substitution of biological medicines was currently permitted in
Ireland. Most pharmacists (59%) answered correctly that it was not,
some pharmacists (30%) responded that they did not know and 10%
believed it was permitted. Pharmacists were then asked how
comfortable they would be with substituting a biological medicine
Table 1
Physician sample characteristics (Medical Specialists and General Practitioners).
Characteristic Medical Specialists [n (%)] General Practitioners [n (%)]
Years registered as medical practitioner
<5 0 (0%) 45 (18%)
5e9 7 (7%) 40 (16%)
10e14 20 (20%) 29 (11%)
15e19 25 (25%) 34 (13%)
20e29 35 (34%) 65 (26%)
>30 15 (15%) 40 (16%)
Position
Hospital based consultant 85 (83%)
Specialist registrar 10 (10%)
Other non-consultant hospital doctor 6 (6%)
Retired consultant 1 (1%) N/A
Medical speciality
Nephrology 23 (22%)
Rheumatology 18 (17%)
Gastroenterology 16 (16%)
Endocrinology 10 (10%)
Neurology 10 (10%)
Dermatology 7 (7%)
Haematology 7 (7%)
Othera 3 (3%)
Oncology 4 (4%)
Haematology/Oncology 4 (4%) N/A
a Pathology (n ¼ 1), neurosurgery (n ¼ 1), rehabilitation (n ¼ 1).
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Fig. 1. Familiarity with the term biosimilar. Survey question: “Which of the following best describes how familiar you are with the term biosimilar?”
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in a situation where substitution was permitted. Of the pharmacist
respondents, 14% indicated they would be comfortable changing a
biologic prescribed by a consultant to a biosimilar. However, the
majority of pharmacists (58%) indicated that they would only be
comfortable changing a patient's medicine from an originator to a
biosimilar with the agreement of the prescriber. A proportion of
pharmacists (27%) responded that they were not comfortable with
substitution.
3.8. Prescriber concerns
In order to explore perceived concerns on the use of biosimilar
medicines, medical specialists were asked to rate their level of
concern, relating to six commonly debated topics around bio-
similars (Table 2). Medical specialists indicated that they had
concerns (ranging from slight to extreme) in relation to: trace-
ability (62%), quality (73%), safety proﬁle (78%), efﬁcacy proﬁle
(79%), immunogenicity (81%), and efﬁcacy in extrapolated in-
dications (84%).
3.9. Sourcing medical information
All healthcare professionals (n ¼ 473) were asked how
frequently they used certain resources to learn about the details of
biological medicines for prescribing, dispensing or monitoring.
Frequent use of information resources was assumed when medical
specialists and GPs indicated that they used the resource ‘a mod-
erate amount’ or ‘a great deal’ on a 5 point Likert scale. Medical
specialists (n ¼ 101) reported frequent use of guidelines from
professional societies (72%), published literature (68%) and
21% 25% 18%
23%
64%
68%
54%
77%
15%
7%
28%
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Fig. 2. Understanding of the term biosimilar. Survey question: Would you consider biosimilars to be the same as generic medicines?
The analysis excludes healthcare professionals who previously indicated that they never heard of the term biosimilar.
*Physicians were offered three options (yes, no and don't know).
**Pharmacists were only offered two options (yes and no). 1% of pharmacists did not respond.
5%
8%
13%
9%
21%
35%
48%
38%
42%
34%
18%
25%
27%
20%
19%
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2%
6%
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Switch with same clinical outcome
(n=329**)
Same clinical outcome (n=331**)
Same indicaƟon (n=458*)
IdenƟcal structure (n=460*)
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Fig. 3. Perceptions of biological medicines with the same INN. Survey question: If two biological medicines (e.g. originator and biosimilar) have the same INN do you think this means
that: i) the medicines are structurally identical, ii) the medicines are approved for the same indications, iii) patients can safely receive either medicine with the same clinical outcome and iv)
patients can be safely switched during treatment with the same clinical outcome.
*Questions asked to medical specialists, GPs and pharmacists.
**Questions asked to medical specialists and GPs only.
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educational events (63%). Of the total GP respondents (n ¼ 247) a
signiﬁcant proportion (58%) frequently relied on national or hos-
pital formularies (such as the British National Formulary). A full
comparison between pharmacists and physicians cannot be made
as the pharmacist questionnaire listed less learning resource op-
tions and a different 3 point Likert scale was used. Despite these
differences, it was apparent that pharmacists (n ¼ 125) were more
likely than other professions to use medical information from the
manufacturer/marketing authorisation holder, with 44% of
pharmacists reporting that they ‘always’ used medical information
from the manufacturer to learn about details of biological medi-
cines. In contrast, only 13% of medical specialists and 7% of GPs
responded that they used this information source frequently. The
European Public Assessment Report (EPAR) was the least consulted
resource of all the options provided. Most medical specialists (85%)
and GPs (94%) indicated that they rarely or never used this
resource. A similar patternwas observed for pharmacists withmost
(90%) indicating that they never consulted the EPAR. However, all
19%
28%
67%
14%
23%
21%
67%
49%
12%
0% 20% 40% 60% 80% 100%
Switch when paƟent has poor response
(n=43)
Switch  (n=43)
Treatment iniƟaƟon (n=43)
Likely or extremely likely Neutral Unlikely or extremely unlikely
Fig. 4. Prescribing patterns of medical specialists who prescribe biosimilars. Survey question: If both an originator medicine and a biosimilar were available to you for prescribing how
likely would it be that you would carry out the following: (i) prescribe a biosimilar to a patient on treatment initiation, (ii) switch from an originator medicine to a biosimilar when a patient
is clinically stable and (iii) switch to a biosimilar when a patient has had a poor clinical response to the originator medicine.
1%
61%
35%
3%
2%
49%
43%
5%
0% 10% 20% 30% 40% 50% 60% 70%
Don't know
No- this should be the prescriber decision
Yes- if agreed with clinican in advance
Yes
Treatment iniƟaƟon (n=95) During a paƟent's treatment course (n=95)
Fig. 5. Attitudes to pharmacist-led substitution held by medical specialists. Survey question: Do you think substitution of a biological medicine by a pharmacist could be appropriate (i)
on treatment initiation and (ii) during a patient's treatment course.
Table 2
Concerns relating to biosimilars amongst medical specialists (n ¼ 93). Survey question: In comparison to originator medicines do you have any concerns speciﬁcally about bio-
similars in each of the following areas?.
Not at all concerned Slightly concerned Somewhat concerned Moderately concerned Extremely concerned Don't know
Traceability 32% 19% 17% 16% 9% 6%
Quality 24% 24% 15% 24% 11% 3%
Safety proﬁle 20% 31% 15% 22% 10% 2%
Efﬁcacy proﬁle 19% 22% 18% 26% 13% 2%
Immunogenicity 17% 30% 12% 22% 16% 2%
Efﬁcacy in extrapolated indications 9% 23% 22% 22% 19% 6%
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professions reported comparable use of the Summary of Product
Characteristics (SmPC) as a learning resource with 52% of medical
specialists and 43% of GPs claiming frequent use, whilst 50% of
pharmacists indicated that they ‘always’ used this resource.
4. Discussion
There are 28 biosimilars currently licensed for use in Europe
(EMA, 2017c). Impending patent expiry dates of many top selling
biological medicines (IMS Institute, 2016) means that more bio-
similars are becoming available, offering healthcare professionals
wider choices in the brands of biological medicine they choose to
treat their patients. Consequently, healthcare professionals need to
make informed treatment choices for their patients. A postal survey
of community pharmacists was conducted in August 2015. An on-
line survey of medical specialists and GPs was then conducted
during April and May 2016. Surveys were carried out in Ireland
with the common aim of assessing awareness of and attitudes to
biosimilars. The professions were chosen as all are directly involved
in the care of patients receiving biological medicines. To the best of
our knowledge this is the ﬁrst published report in which ﬁndings
from a survey in relation to biosimilars has been presented for 3
healthcare professional groups across primary and secondary care.
In order to explore levels of awareness across the different
professions, survey respondents were asked to indicate how
familiar they were with the term ‘biosimilar’. Many medical spe-
cialists claimed to be very familiar with a complete understanding
(44%), or familiar with a basic understanding (41%). The same
question was asked in a survey of European medical specialists in
2013 and in this instance 22% claimed to have a complete under-
standing and 54% claimed a basic understanding of the term
(Dolinar and Reilly, 2014). Although the results are not directly
comparable due to the different sample composition our ﬁndings
suggest that perceived familiarity with the term ‘biosimilar’ has
increased amongst medical specialists since this time. Indeed, a
recent survey of Inﬂammatory Bowel Disease experts suggests that
since 2013 there are fewer concerns about and more conﬁdence in
the use of biosimilars in clinical practice (Danese et al., 2016).
Although familiarity amongst medical specialists is high, we found
that this level of familiarity was not consistent across the 3 pro-
fessions. Responses from GPs indicated that this group were least
familiar with the term, with one in four GPs responding that they
had never heard of the term ‘biosimilar’. This lack of familiarity may
be attributed to the fact that GPs are not directly involved in the
prescribing of biological medicines. However, GPs are certainly
involved in the treatment of patients receiving biological medicines
therefore it is important that GPs are informed about biosimilars.
The level of actual understanding amongst some healthcare pro-
fessionals may also be questionable. The differences between
generic and biosimilar medicines is widely communicated in the
published literature (Weise et al., 2012; deMora, 2015). Despite this
we found that one in ﬁve healthcare professionals who had pre-
viously heard of the term ‘biosimilar’ responded that biosimilars
were the same as generic medicines.
In Europe, biosimilars have the same international non-
proprietary name (INN) as their reference medicines. Re-
spondents were asked if they agreed with various statements
relating to two biological medicines (e.g. originator and biosimilar)
with the same INN. The responses revealed some misconceptions.
For instance, 47% of all healthcare professional respondents
mistakenly agreed that two biological medicines with the same INN
would have an identical structure. In relation to clinical outcome, a
notable proportion of the physician respondents were either
neutral (34%) or disagreed (22%) with the statement that patients
could safely receive either an originator or biosimilar medicine
with the same INN and still expect the same clinical outcome.
Biosimilars are approved on the basis that they have demonstrated
comparable efﬁcacy and safety to their reference medicine (EMA,
2014); the high level of neutral answers and disagreement with
the statement suggests that this fundamental regulatory principle
could be better communicated to healthcare professionals.
The survey ﬁndings indicate that the majority of healthcare
professionals (79%) practise in line with recommendations by using
brand name to identify biological medicines for prescribing,
recording or dispensing; however, traceability by batch number
appears low. Of the 67 physicians who had previously reported a
suspected adverse reaction for a biological medicine (excluding
vaccines) many (57%) responded that they had never or rarely
included the batch number. This ﬁnding echoes conclusions drawn
from analyses of EU and national spontaneous reporting systems
which indicated traceability to batch level for biological medicines
is poor (Vermeer et al., 2013; Klein et al., 2015). Reporting of batch
numbers enables links to be established between manufacturing
process changes and rare adverse reactions. Ensuring the trace-
ability of batch numbers in clinical practice is not without its
challenges (Vermeer et al., 2015). However, education of healthcare
professionals around the speciﬁc pharmacovigilance consider-
ations applicable to biological medicines, may improve batch
number traceability in adverse reaction reports and contribute to
ongoing post-marketing surveillance.
In Ireland it is currently recommended that the treating physi-
cian is involved in any decisions to change the medicine a patient
receives from its reference to a biosimilar medicine or vice versa
(HPRA, 2015). Changing of a patient's treatment in this manner is
often referred to as ‘switching’ (EC, 2013). When asked about
switching many physicians (42%) had no deﬁnite opinion on
whether biosimilars could be used interchangeably with their
originator medicines. Of the 43 medical specialists who currently
prescribe biosimilar medicines, more would be likely to prescribe
the biosimilar on treatment initiation (67%) thanwould be likely to
switch a patient to a biosimilar after treatment had been initiated
with the originator (28%). The differences in responses could reﬂect
the fact that in Ireland there is currently no national guidance in
relation to switching. In contrast, some medical societies in the UK
have begun to encourage this practice on economic grounds (BSG,
2016; RCP, 2016). One UK hospital has recently highlighted their
switching programme which involved consultations with patients,
robust traceability systems as well as appropriate clinical moni-
toring and surveillance (Underhill, 2016). If biosimilar uptake is to
be encouraged in Ireland further guidance in relation to switching
and how best to manage this practice may be needed. Notably 19%
of medical specialists who currently prescribe biosimilars indicated
that they would be likely to switch to a biosimilar when a patient's
response to the reference medicine was inadequate. Although the
sample size is small, this response highlights the need to inform
prescribers that biosimilars are equivalent treatments to their
reference medicines offering comparable patient outcomes.
A number of countries in Europe, including Ireland, have policies
in place to prevent pharmacist-led substitution of biological med-
icines (Thimmaraju et al., 2015). The results of our survey reﬂect the
national policy with <5% of medical specialists indicating that
substitution of a biological medicine by a pharmacist could be
appropriate. Interestingly, a notable proportion of medical spe-
cialists were supportive of pharmacist led substitution both on
treatment initiation (43%) and during a patient's treatment course
(35%) if it was agreed with the clinician in advance; though the
questionnaire did not probe what level of agreement would be
necessary. The majority of medical specialists did, however, believe
that decisions of this nature should be prescriber led, which may
also reﬂect some of the challenges associated with the substitution
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of biological medicines at pharmacy level (Weise et al., 2012). An
additional challenge includes pharmacist attitudes, as this group
are ultimately responsible for the implementation of substitution
policies at pharmacy level. Only 14% of pharmacist respondents
stated they were comfortable with substitution (without prescriber
agreement) which echoes ﬁndings from previous research indi-
cating pharmacists may have reservations about assuming such
responsibilities (Beck et al., 2017).
The EMA has over ten years' experience in the regulation of
biosimilars which has led to the approval of 28 safe and effective
biosimilar medicines in Europe. Despite this fact there is continued
discussion in the published literature suggesting that there are
concerns amongst healthcare professionals around the use of bio-
similars (Mellstedt et al., 2008; Schimizzi, 2016). Such concerns are
likely to be compounded by lack of familiarity with the concept of
biosimilarity (Grabowski et al., 2015; Beck et al., 2016, 2017). When
asked about such perceived concerns, most medical specialists
indicated some level of concern for each of the following commonly
debated issues: efﬁcacy in extrapolated indications, traceability,
quality, safety proﬁle, efﬁcacy proﬁle and immunogenicity. This is
despite the fact that these commonly cited ‘concerns’ have been
addressed and clariﬁed at a regulatory level (Weise et al., 2012,
2014). Although the questionnaire did not probe the speciﬁc rea-
sons for each concern, clearly there is a need to address such issues
in ongoing educational initiatives on biosimilars. A recent example
of such an initiative includes an information guide on biosimilars
for healthcare professionals which has been jointly produced by the
EMA and European Commission (EMA and EC, 2017).
In order to establish how best to target educational initiatives
survey respondents were asked how frequently they used various
information sources to learn about the details of biological medi-
cines for prescribing and monitoring. A sizable proportion of those
surveyed claimed frequent use of the SmPC which is similar to
ﬁndings from a recent survey of European medical specialists
(Hallersten et al., 2016). In Europe clinical information contained in
the SmPC of a biosimilar is generally identical to information con-
tained in the SmPC of the reference medicine; a single statement is
included in the prescribing information to indicate that a biological
medicine is approved as a biosimilar. In contrast to the SmPC, the
EPAR provides more comprehensive information on the evidence
submitted to support approval of a biosimilar. The EPAR for a bio-
similar medicine is available on the EMA website. The ﬁndings of
the present study suggest this resource is rarely used by healthcare
professionals in Ireland, suggesting that the EPAR which outlines
the totality of evidence approach on which the biosimilar philos-
ophy is based, is either not well known or not accessible to
healthcare professionals. The survey ﬁndings suggest that targeted
communication to medical specialists via professional societies,
published literature and educational events could help to reduce
the information gap on biosimilar medicines. The most appropriate
communication channels for GPs and community pharmacists are
less clear, but liaison with representative societies may facilitate
knowledge transfer to these professions.
The potential for biosimilars to reduce drug expenditure and
increase patient access to high cost medicines is recognised by the
Irish Health Service Executive - Medicines Management Pro-
gramme (MMP, 2016). However, the current lack of formal guid-
ance, policies or incentives encouraging the prescribing of
biosimilars is likely a factor in Ireland's low uptake of these prod-
ucts (IMS Health, 2016; IMS Health, 2017). It might be expected,
that healthcare professional attitudes towards biosimilars would
echo their attitudes towards genericmedicines. In Ireland, attitudes
towards generic medicines have evolved over time. A 1997 survey
of Irish GPs found that many were concerned about the quality and
reliability of generic medicines (Feely et al., 1997). Pharmacists too,
were reported to have concerns about the reliability of generic
medicines owing to concerns over bioavailability, quality and pa-
tient complaints (Murphy, 1997). Escalating healthcare costs and
low generic uptake (Brink et al., 2013) resulted in the introduction
of generic substitution and reference pricing in Ireland in 2013.
Surveys conducted at this time indicated that attitudes towards
generics had changed considerably, with general positive opinions
on generics being reported by GPs and pharmacists (Dunne et al.,
2014; O'Leary et al., 2015). Stakeholder attitudes are constantly
evolving, so it is likely that a combination of policy developments,
national guidance on the use of biosimilars and educational ini-
tiatives will all contribute to improving healthcare professional
perceptions of biosimilars.
The study has some limitations including the fact that the
ﬁndings cannot be extrapolated to healthcare professionals in
countries with high biosimilar uptake or where policies and in-
centives relating to the prescribing of biosimilars are in place.
Owing to the differing response rates, it was not possible for each
medical discipline to be equally represented in the sample of
medical specialists. Selection biases could also be present as
healthcare professionals that are less familiar with biosimilar
medicines, may have been less willing to participate in the survey.
There are also some minor methodological differences in the
collection of survey responses between the pharmacist and physi-
cian studies. The provision of a honorarium to pharmacists, and not
physicians, and the different methods employed for survey distri-
bution (postal for pharmacists and online for physicians) may have
induced participation biases. There was a 9 month time delay in
distribution dates of the pharmacist questionnaire (August 2015)
and physician questionnaires (April/May 2016). Although, health-
care professional's knowledge and experience may have evolved
during this time, the delay is unlikely to have a signiﬁcant impact in
the context of an Irish survey as rates of biosimilar usage in Ireland
remain low and did not differ signiﬁcantly between 2015 and 2016
(IMS Health, 2016; IMS Health, 2017). It should also be acknowl-
edged that hospital pharmacists were not represented in the study.
Previous surveys have suggested that hospital pharmacists have an
increased awareness of the biosimilar concept (Beck et al., 2017).
While the majority of questions were common to all survey
groups, some questions were tailored for either the pharmacist or
physician groups. Consequently, only ﬁndings from common
questions are compared. Community pharmacists, unlike physi-
cians, were not provided with a ‘don't know option’ when asked
‘Would you consider biosimilars to be the same as generic medi-
cines’ (Fig. 2). However, it is unlikely that the provision of this extra
option to pharmacists would have altered the ﬁnding that 1 in 5
healthcare professionals responded that biosimilars were the same
as generics. In the case of physicians, survey items were further
developed so more in depth information could be assessed. Unlike
physicians, pharmacists were not asked if they agreed with state-
ments pertaining to clinical outcome for two biological medicines
with the same INN (Fig. 3). Pharmacists were also provided with
less learning resource options and a different Likert scale in the
question that addressed the sourcing of medical information (sec-
tion 3.9). The physician questionnaires were tailored for either
medical specialists or GPs. Only questions that were directly rele-
vant to GP practice were included on the GP questionnaire, there-
fore questions relating to prescribing practices and attitudes
towards substitution of biological medicines were excluded.
In conclusion this survey was the ﬁrst study that compared
awareness and attitudes to biosimilar medicines amongst medical
specialists, GPs and community pharmacists based in Ireland. We
found that familiarity with the term biosimilar varied between the
three professions, with the highest level of familiarity among
medical specialists, followed by community pharmacists and then
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GP's. However, 21% of those surveyed responded that a biosimilar
was the same as a generic medicine, which could suggest a lack of
awareness among some respondents on the differences between
generic and biosimilar medicines. Medical specialists who
currently prescribe biosimilars were more likely to do so on
treatment initiation than switch from an originator to a biosimilar
during a patient's treatment course. The majority of medical spe-
cialists (>95%) were not supportive of pharmacist-led substitution
indicating that they believe decisions to change a patients medicine
should be either prescriber led or agreed with the prescriber in
advance. The extent of concerns held by medical specialists in
relation to biosimilars were highlighted, despite the fact that to
date the biosimilars licensed in the EU have proven to be as safe and
efﬁcacious as their reference medicines. The development of policy
and national treatment guidance on the use of biosimilar medicines
may ensure that Ireland beneﬁts directly from their increasing
availability. Healthcare professionals may also beneﬁt from tar-
geted educational initiatives to reduce the information gap on
biosimilar medicines.
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